Friday, September 18, 2026

Astra for Law plus 230M-source legal search puts OpenAI directly on top of Harvey's wedge — reprice any legal-AI exposure you hold.

Underwrite a fear-driven regulatory freeze as a real tail risk on AI infra and energy positions, not just a talking point.

A new category of safety-audit institutions is being created by fiat this month; funding or staffing one is now a real venture and influence play.

Jev's claimed 40–400x cost delta on classification work means your portfolio's per-token inference budgets are mispriced for any high-volume decision task.

Chinese open-weight supply keeps expanding while US labs debate slowing down — factor that asymmetry into any inference-pricing or moat assumption.

If you want exposure to the safety panic rather than a hedge against it, defensive security labs with proprietary attack-outcome data are the trade.

Run one pod for six weeks with a named DRI before touching a portfolio company's marketing org chart; the cut-headcount board pressure is backwards.

Jensen rotating out of picks-and-shovels while CoreWeave sells equity and converts into the same tape is your cue to check infra exposure duration.

The SaaS-is-dead short has now failed on revenue and price; reprice application-layer software on complement rather than substitution.

A single ITC-style import ruling froze 61% of a wearable's revenue for five months — treat patent exposure as a primary diligence line in hardware.

The pre-IPO pop is the entire thesis on this round; if Anthropic's $65B revenue lead holds, the $1.5T exit mark doesn't clear.

Content licensing is heading to real money because the labs' own documents concede supply collapse — reconsider any publisher asset priced for terminal decline.

Nothing to act on; filter these out of the feed so they stop diluting the queue.

Nothing to act on; the duplicate confirms your newsletter ingestion needs a dedupe rule.

Smith's "under 1% of enterprise data absorbed" is the number to quote when a portfolio CEO claims AI deployment is done.

Adopt the three-question post-mortem — what did the run cost, what did it buy, what did we learn — before your agent bills outrun any attributable output.

Audit which agent skills your engineering teams have installed from public repos this week — the auto-update path was the attack surface, and one vendor may still be open.

A 5% compute-share trigger would land on a short list of names you likely own; start modeling what SIFI-style oversight does to their capital plans.

Another founder-operator has turned his newsletter audience into a paid agent-platform beta — the distribution-to-product path is now standard, watch for it in your deal flow.

Worth the hour only if you need MGI's framing on cross-economy divergence for an LP letter; otherwise skip.

Point your portfolio companies' hiring managers at Sales Combine before October 3 — it is a free, pre-screened channel for early sellers.

The concentration-versus-diversification line is the cleanest articulation of the allocation decision you are already making on AI exposure.

Expect enterprise AI deals to slip on buyer hesitancy over the next two quarters, and price safety-evaluation orgs as a genuine talent competitor to the labs.

Skim the list for the quieter investors and operators; that's the only part of a power ranking you don't already know.

Worth an hour for the gross-margin discussion if you hold AI-native SaaS where inference costs are eating the 80% line.